Abstract
Combination vaccines date back to 1948 when diphtheria, tetanus and pertussis vaccines were combined into DTP shot. Today the most common pediatric combination vaccine is the hexavalent vaccine, which includes DTP plus Hib, IPV polio and Hepatitis B components. Several preparations are now available. Hexavalent vaccine facilitates childhood immunization schedules and increase vaccine compliance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Aristegui J, Dal-Re R, Diez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 2003;21:3593–600.
Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C, Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998;17(11):1026–33.
Chiappini E, Petrolini C, Caffarelli C, Calvani M, Cardinale F, Duse M, Licari A, Manti S, Martelli A, Minasi D, Miraglia Del Giudice M, Pajno GB, Pietrasanta C, Pugni L, Tosca MA, Mosca F, Marseglia GL. Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology. Ital J Pediatr. 2019;45(1):145. doi: https://doi.org/10.1186/s13052-019-0742-7. PMID: 31744514; PMCID: PMC6862761.
Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20(11 Suppl):S10–8.
Dewan KK, Linz B, DeRocco SE, Harvill ET. Acellular Pertussis Vaccine Components: Today and Tomorrow. Vaccines (Basel) 2020;8(2):217. doi: https://doi.org/10.3390/vaccines8020217
Dolhain J, Janssens W, Mesaros N, Hanssens L, Fierens F. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer. Expert Rev. Vaccines. 2018;17(6):513-524. doi: https://doi.org/10.1080/14760584.2018.1419070.
Dolhain J, Janssens W, Sohn WY, Dindore V, Mukherjee P. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert Rev Vaccines 2019;18(9):921−933. doi: https://doi.org/10.1080/14760584.2019.1646643.
ECDC. Shortage of acellular pertussis-containing vaccines and impact on immunisation programmes in the EU/EEA. http://ecdc.europa.eu/en/publications/Publications/RRA-shortage-of-aP-containing-vaccines.pdf
Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996;348(9043):1688–92.
Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria tetanus pertussis containing acellular pertussis. Lancet 1999;354:2063–8.
Esposito S, Tagliabue C, Bosis S, Ierardi V, Gambino M, Principi N. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infect 2014;20(Suppl 5):76–85.
Lee AW, Jordanov E, Boisnard F, Marshall GS. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers. Expert Rev Vaccines 2017;16(2):85–92.
Mallet E, Belohradsky BH, Lagos R, Gothefors L, Camier P, Carrière JP, Kanra G, Hoffenbach A, Langue J, Undreiner F, Roussel F, Reinert P, Flodmark CE, Stojanov S, Liese J, Levine MM, Muñoz A, Schödel F, Hessel L, Hexavalent Vaccine Trial Study Group. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004;22(11–12):1343–57.
Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother 2015;11(9):2132–41.
Marshall GS, Adams GL, Leonardi ML, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, Lee AW. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics 2015;136(2):e323–32. doi:https://doi.org/10.1542/peds.|2014-4102.
Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R. PRI02C study group. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Vaccine 2017;35(30):3764–72. doi: https://doi.org/10.1016/j.vaccine.2017.05.043. Epub 2017 Jun 2.
Martinón-Torres F, Diez-Domingo J, Feroldi E, Jordanov E, B'Chir S, Da Costa X. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers. Pediatr Infect Dis J 2019;38(3):317-322. doi: https://doi.org/10.1097/INF.0000000000002231.
Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther 2013;13(4):575–93. doi: https://doi.org/10.1517/14712598.2013.774368.
Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F. New perspectives for hexavalent vaccines. Vaccine 2018;36(36):5485-5494. doi: https://doi.org/10.1016/j.vaccine.2017.06.063. Epub 2017 Jul 1. PMID: 28676382.
Obando-Pacheco P, Rivero-Calle I, Raguindin PF, Martinón-Torres F. DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age. Expert Rev Vaccines 2019;18(11):1115-1126. doi: https://doi.org/10.1080/14760584.2019.1690457. Epub 2019 Dec 10. PMID: 31697185.
Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, Gómez IP, Liese J, Knuf M. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine 2018;36(7):986-996. doi: https://doi.org/10.1016/j.vaccine.2018.01.005. Epub 2018 Jan 12.
Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, Francia F, Lopalco P, Prato R, Russo R, Villani A, Franco EHexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59(2):E107−E119. PMID: 30083617; PMCID: PMC6069402.
Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Global Infect Dis 2011;3(1):63–72.
Syed YY. DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination. Paediatr Drugs. 2019;21(5):397−408. https://doi.org/10.1007/s40272-019-00353-7. Erratum in: Paediatr Drugs. 2019;21(6):501
Syed YY. DTaP5-HB-IPV-Hib Vaccine (Vaxelis®): a review of its use in primary and booster vaccination. Paediatr Drugs 2017;19(1):69–80. doi: https://doi.org/10.1007/s40272-016-0208-y.
Thollot F, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Pediatr Infect Dis J 2014;33(12):1246–54.
Vennemann MM, Butterfass-Bahloul T, Jorch G, Brinkmann B, Findeisen M, Sauerland C, Bajanowski T, Mitchell EA, GeSID Group. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 2007;25(2):336–40.
Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J 2017a;36(2):209–15. doi: https://doi.org/10.1097/INF.0000000000001406.
Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine 2017b;35(3):452–8. doi: https://doi.org/10.1016/j.vaccine.2016.11.053.
Wang S, Tafalla M, Hanssens L, Dolhain J. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines 2017;16(11):1095−1105. doi: https://doi.org/10.1080/14760584.2017.1383157. Epub 2017 Oct 3. PMID: 28971707.
Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix Hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009;8(6):663–78.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Martinón-Torres, F. (2021). Pediatric Combination Vaccines. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-030-77173-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-77173-7_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-77172-0
Online ISBN: 978-3-030-77173-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)